Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs

American Journal of Managed Care

Volumn 13, Issue 1 SUPPL., 2007, Pages

  Naslund, Michael ^a   Black, Libby ^b   Eaddy, Michael ^b   Batiste, LaKeasha R ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COST CONTROL; COST OF ILLNESS; DRUG WITHDRAWAL; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; AZASTEROIDS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33847231619     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S83-S89.
2. Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4 suppl 1):2-7.
3. Roehrbom CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(suppl 9):S3-S14.
4. McConnell JD, Roehrbom CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
5. Avodart® (dutasteride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2005. Available at: http://us.gsk.com/products/ assets/ us_avodart.pdf. Accessed January 8, 2007.
6. Proscar® (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; January 2006. Available at: http://www.merck.com/ product/ usa/pi_circulars/p/proscar_pi.pdf. Accessed January 8, 2007.
7. Barkin J, Guimarães M, Jacobi G, et al. Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha reductase inhibitor dutasteride. Eur Urol. 2003;44:461-466.
8. Roehrbom CG, McConnell JD, Barry MJ, et al. Guideline on the management of benign prostatic hyperplasia (BPH). 2003; updated 2006. American Urological Association. Available at: http://www.aua2004.org/ guidelines/bph.cfm. Accessed January 8, 2007.
9. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179-2184.
10. Hagerty JA, Ginsberg PC, Harkaway RC. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in clinical practice. Poster presented at: the 2004 Annual Meeting of the American Urological Association; May 8-13, 2004; San Francisco, Calif. Poster 1353.
11. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Hyattsville, Md: Centers for Disease Control and Prevention; 1979.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
14. Disease Staging: Coded Criteria. 5th ed. Ann Arbor, Mich: Thomson Medstat; 2003.
15. Roehrbom C, Andriole G, Schalken J, et al. Dutasteride, a novel dual 5α-reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients. Poster presented at: XVIIIth Congress of European Association of Urology; March 12-March 15, 2003; Madrid, Spain. Poster 635.
16. Baldwin KC, Ginsberg PC, Roehrbom CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology. 2001;58:203-209.